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Historical Events in Microbiology(Biochemistry)
     
; 
 
current textbook style 
 Leading textbooks of microbiology are now heavy encyclopedic 
tomes of ca. 1,000 pages; in an early chapter, only about 25 pages deal 
with the history of the subject. Typically, some of pioneering 
researches of several 19th century “giants” (e.g., Pasteur and Koch) are 
described and later events are summarized in a long table of one-line 
entries, telegraphic style.   
 I have compiled part of an “example table” by combining entries 
from several recent texts (see below). They are given verbatim, except 
for minor editing to improve the English. In tables of this kind, the 
name of the investigator is sometimes not included.   The first 
historical observation and depiction of microorganisms is almost 
always given erroneously. In 1665, Robert Hooke described the 
microfungus Mucor; about eleven years later, Antoni van 
Leeuwenhoek observed bacteria (see Gest 2004 and 2009: The 
discovery of microorganisms by Robert Hooke and Antoni van 
Leeuwenhoek, Fellows of the Royal Society, Notes and Records of the 
Royal Society vol. 58, pp. 187-201, 2004; Homage to Robert Hooke 
(1635-1703): New Insights from the Recently Discovered “Hooke 
Folio.” Perspectives in Biology and Medicine 52(3): 392-399, 2009. 
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A typical textbook table of notable events in microbiological 
(biochemical) research 
    1835   A. Bassi discovers that a silkworm disease is caused by a 
                fungus 
    1881   L. Pasteur developed the first artificial vaccine  (vs anthrax) 
    1885   T. Escherich discovers Bacterium coli, a cause of infant  
       diarrhea (later renamed Escherichia coli) 
    1899   M. Beijerinck  The concept of a virus is proposed to explain 
       tobacco mosaic disease 
1929 A. Fleming discovers penicillin 
1937 H. Krebs discovers the tricarboxylic acid cycle 
H. Wood working with propionic acid  bacteria is the first to 
discover that heterotrophs utilize CO2 in metabolism 
    1944   O. Avery, C. Macleod and M. McCarty  DNA is genetic  
       material 
    1945   Max Delbruck and S. Luria   Bacteriophage replication  
       mechanism is elucidated 
    1946   E. Tatum and J. Lederberg   Bacteria transfer DNA by 
       conjugation 
    1952   J. Lederberg and N. Zinder  Bacterial transduction 
                A. Hershey and M. Chase show that bacteriophages inject 
        DNA into host cells 
    1953    J. Watson and F. Crick propose the double helix structure for 
                DNA 
 4 
    1964  C. Yanofsky and colleagues demonstrate linear 
               correspondence between a gene segment and a protein 
               sequence 
    1966  M. Nirenberg, H. G. Khorana and others decipher the DNA 
       genetic code 
   1969   T. Brock and H. Freeze   Isolation of Thermus aquaticus,  
      source of Taq DNA polymerase 
   1973   S. Cohen, A Chang, R. Helling, and H. Boyer   Recombinant  
      DNA 
   1982   S. Prusiner   Prions, infectious agents consisting solely of  
      proteins, are discovered 
 
 How would a new generation of young scientists learn how these 
discoveries were made?  Who were these investigators?  Where did 
they work?  How long did it take for the discovery to be made – one 
month?  one year?  ten years? 
 
Two Snapshots in the History of Microbiology 
 The bubonic plague is raging in London -- more than 7,000 deaths 
each week. Pharmacist William Boghurst, a heroic helper, explained the 
disease as follows: 
1665 
 “Plague or pestilence is a most subtle, peculiar, insinuating, 
 venomous, deleterious exhalation arising from the maturation  
 of the faeces of the earth extracted in the aire by the heat of the  
 sun and difflated from place to place by the winds and most tymes 
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 gradually but sometymes immediately aggressing apt bodyes.” 
 In the same year, Robert Hooke, Fellow of the Royal Society of 
London, published his great classic Micrographia, which contained the 
first description and drawing of a microorganism, the microfungus 
Mucor. Hooke, a prolific inventor, described Mucor’s very thin 
cylindrical and transparent stalks which had “a white knob that grew 
on the top of each of them.” His observations were made with a 
microscope of his own construction. 
 
 Dr. Alexandre Yersin, an officer in the French Medical Colonial 
1894 
Corps, is sent to Hong Kong at the suggestion of Louis Pasteur. A 
plague epidemic had developed in the city; people were dying by the 
hundreds. Yersin is instructed to study the outbreak and try to isolate 
the causative agent. With help from an English priest, he manages to 
build a small shack to live in, outside, but adjoining, a hospital. The 
shack contains a small folding bed and a very small makeshift 
laboratory. Yersin gave a few dollars to two English sailors who were 
helping to take care of the hospital morgue. With their connivance he 
got into the morgue for a few minutes and had access to the corpse of a 
patient who had just died of plague. Yersin punctured the patient’s 
swollen inguinal lymph node (i.e., bubo) with a sterile pipette, ran to his 
small laboratory and went to work. He wrote in his notebook: June 20, 
1894  “The specimen is full of microbes, all looking alike, with rounded 
ends, staining very poorly (gram negative); this is without question the 
microbe of plague.” 
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 Yersin then examined blood, lymph nodes and other organs of 
dead rats lying on the streets and found they were full of the same 
bacilli that he had observed in the people dying of the plague.  He 
named the organism Bacterium pestis.  It was later renamed Yersina 
pestis. 
 
 The historical record shows that explanations of complex 
biological phenomena usually required the efforts of many scientists 
over long periods of time.  In a number of instances, there were sudden 
surges of clarification when a lone investigator or a small group 
performed a crucial experiment, perhaps using a new technique, or 
reinterpreted known facts in a new way. 
 What factors predispose to creativity in scientific research?  This 
question is discussed in the philosophical writings of Max Perutz who 
was awarded a Nobel Prize in Chemistry (1962) for solving the crystal 
structure of hemoglobin.  His pioneering work paved the way for many 
later researches of proteins important in the metabolism of 
microorganisms and other forms of life. Perutz’s success was based on 
persistent and very hard work, inspirations, and a web of interactions 
with other scientists at just the “right times.”  In his 2003 book (see 
Further Reading, at end): 
 “There is little benefit in following scientists’ daily grind but 
much in tracing the unique combinations of theoretical knowledge and 
manual skills, the web of personal encounters and accidental 
observations, the experience, temperament, moods and clashes that go 
into the making of discoveries, even though the crucial leap of the 
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mind is often impenetrable. There is also something to be said for 
finding out why others, seemingly just as able, were too blind to grasp 
what Nature tried to tell them.”  
 
 Much has been written comparing basic (“pure”) research and 
applied (“industrial”) research. Applications of knowledge from 
microbiology, biochemistry and molecular biology are now especially 
prominent in biotechnology ( i.e., “biotech”). A very large number of 
biotech companies have been established, ranging from “start-ups” 
with less than 10 employees to organizations with thousands of 
scientific personnel. Many graduate students and post-doctoral fellows 
are now faced with making a career choice—academic science vs 
biotech.  The choice dictates the kind of life style that ensues, and it is 
a fundamental decision. 
Basic vs applied research 
 According to a recent book by Steven Shapin, the march of 
modern events has led to an entity he calls “The Scientific Life” 
(University of Chicago Press, 2008). This refers to a blend of “relative” 
freedom to do basic research coupled with working on money-making 
projects. Shapin states that his book deals “very substantially with 
American industrial scientists, entrepreneurs, venture capitalists, and 
Organization Men: research managers at electrical and photographic 
firms, team-playing organic chemists, Southern California investors in 
high-tech companies, engineering professors, trying to develop and sell 
intellectual property and to get ahead in their academic careers.” He 
discusses biotech at some length, but apparently forgot to include it in 
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his list.  Shapin’s last chapter is an Epilogue titled “The way we live 
now.” 
 It begins with a photo of a reception at the University of 
California San Diego on a beautiful April day in 2004.  The reception 
is essentially an outdoor “networking” cocktail party on a deck 
attached to an architect-designed building.  Who is there? 
 “They are scientists, engineers, and research physicians; high-
tech and biotech entrepreneurs; CEO, CSOs, and CTOs of start-up 
companies; venture capitalists and angel investors; intellectual 
property lawyers and service providers to the high-tech community; 
and academic administrators basking in pleasure—both at the 
perfection of the day, of course, and, especially, at the sight of all of 
these people assembled on the premises of a major pubic research 
university. It is a visible sign that the university is fulfilling one of its 
major acknowledged functions in a late modern economy, building 
bridges between knowledge making and wealth making, doing the sort 
of things  that make political and business leaders happy.” 
That says it all, in a nutshell. 
 
 A review of Shapin’s book by William Deresiewicz appeared in 
The Nation, March 16, 2009 (“Lab Test,” pp. 23-28). Following are 
some excerpts: 
 Shapin’s narrative begins with the shift from science as a 
calling to science as a job. . . .Does the profit motive distort and 
degrade the unpredictable path of scientific discovery?  Through 
the early decades of the twentieth century, the old notions came 
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under still greater pressure. The allegiance to knowledge for the 
sake of knowledge and consequent elevation of “pure” over 
applied research, the principled disdain for self-enrichment and 
corollary belief in the scientist’s moral superiority, the 
commitment to investigative autonomy and free exploration as 
essential to the scientific project—all these were challenged 
          by the explosive growth of industrial science. . . .  
      “By mid-century [20th], the typical scientist was no longer an  
          independent investigator toiling in splendid isolation or an  
unworldly academic ensconced in an upper floor of the ivory 
tower but an increasingly well-paid company man working 
project to project on tasks 
          selected by superiors with the goal of enhancing the bottom  
          line. . . . 
      “Some scientists, including those with experience in the 
 private sector, deplore what they see as the conformity, 
         hierarchy and materialism of the corporate environment. Others 
         though, are equally disillusioned by academia—not only the  
         burden of teaching duties and the constant scrabble for grant  
         money but the paradoxical fact that universities, having 
         absorbed a great deal of managerial philosophy of late, have 
 created environments that are often more hierarchical, tightly 
 controlled and inimical to intellectual autonomy, especially for 
          the young scientist, than corporations. Still others welcome the 
          integration of the two spheres. . . . 
      “Does injection of the profit motive into scientific research 
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 distort the kind of questions that get investigated and degrade  
         the quality of the results that get produced?  There are strong  
         reasons to believe that it does.” 
 
 Shapin’s book was also reviewed by H. Allen Orr in The New 
York Review of Books, March 26, 2009 (p. 34, “Which Scientist Can 
You Trust?”).  From his review, the essence of the book emerges quite 
clearly. Much is devoted to the question of whether or not scientists 
are “priests of nature, endowed with exceptional moral competence, or 
ordinary people who have acquired esoteric technical knowledge. . . . 
And to what extent do personal virtues matter in the practice of 
science.” 
 Another topic: Is, or was, research in industrial companies “more 
regimented than in academia”? Again, the answer is obvious despite 
the few examples Shapin gives of companies where a few exceptional 
senior scientists had free time to pursue their own research interests. 
To be sure, the present difficulties of young scientists in obtaining 
research grant funds is a serious problem --“the game of grants” -- but 
stringent review is certainly a mechanism for filtering out research 
plans that are not of basic significance or well designed.  Some of the 
examples Shapin cites for entrepreneurial science (as contrasted with 
academia) are almost entirely based on previous basic research in 
universities, the National Institutes of Health, or independent non-
profit institutes. Orr notes:  “There can be little doubt that, at least in 
some areas of science, particularly biology and information technology, 
entrepreneurial science will grow in size and, possibly, significance.” 
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 It is abundantly clear that in contrast to Shapin’s perception, 
research by individuals or small groups in academia in the decades 
between 1940 and 1990 gave us a Golden Age of Basic Discovery in the 
biological and medical sciences. . . .general biology, biochemistry, 
general and medical microbiology, virology, genetics, molecular 
biology, etc. This led to important advances in medicine, agriculture 
and public health, and biotechnology, now exploited by commercial 
companies. To cite only one of numerous examples, the discovery and 
development of the first antibiotic, penicillin, came from a handful of 
scientists; one in a hospital research laboratory in London and a small 
group of investigators at the University of Oxford. But the basic 
advances did not come from industry to a significant extent. 
 The correct time frame of great strides in understanding major 
aspects of biology was given by Susan Hockfield, President of the 
Massachusetts Institute of Technology (Science, 27 April, 2009;  
p. 1147). She refers to “the convergence of the life sciences with the 
physical sciences and engineering” as follows:   
“The next convergence follows from the elucidation of the 
structure of DNA in the 1950s and from subsequent fundamental 
discoveries in molecular and cellular biology. These discoveries 
created a revolution in the life sciences and drove the 
development of recombinant DNA technology and the launch of 
the biotechnology industry. By the mid-1980s, the explosion of 
data from genomics and proteomics brought about a second 
revolution, further accelerating life science innovation.” 
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There is no doubt that the contributions of the basic ideas and 
experimental studies contributed by industry to these revolutions 
were minor.   
Further comments by Orr: 
“Though generally sound, Shapin’s discussion is in some ways  
         unsatisfying, For one thing, he draws his main evidence for the 
         role of the personal from the interaction of venture capitalists 
         with entrepreneurs, an interaction that has more to do with 
         investing than with science. . . . Also, Shapin’s discussion of  
         industrial science mostly breaks off around the middle of the 
         twentieth century. . . . Is research at Pfizer really shaped by the  
         personal virtues of it scientists?”….While there can be no doubt  
         that the figure of the independent academic scientist has been 
         overly romanticized, when it comes to truly transformational  
         science, it is at least possible that the lone wolf mythology isn’t  
         entirely mythological.”    
 
 Modern biotech originated almost entirely from basic research in 
academia and nonprofit institutes, from research aimed at explaining 
the mechanisms of cell (organism) growth and development. A very 
large number of investigators contributed to the solution of complex 
questions, using diverse experimental systems. Two outstanding 
academic scientists merit particular attention in connection with the 
emergence of biotech, Ernst B. Chain and Joshua Lederberg. 
What history tells us 
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Ernst Chain (1906 – 1979
In 1928, the microbiologist Alexander Fleming was working at 
St. Mary’s Hospital and Medical School in London. His research 
centered on ways of killing pathogenic bacteria with antiseptics, and 
he frequently used staphylococci as the test organism. One day, by 
accident, he noted a strange phenomenon on a discarded Petri dish 
culture. In a circular zone around a contaminant mold colony, all 
colonies of staphylococci had been destroyed. Evidently, the mold must 
have secreted a lethal substance of some kind. The mold was later 
identified as belonging to the genus Penicillium, and Fleming named 
the mysterious secretion 
) 
 Fleming published his observations in 1929, and it is clear that 
he did not realize the potential value of penicillin for treatment of 
infectious diseases. Nine years later (1938), the scene shifts to the 
University of Oxford and Ernst Chain, a refugee from Hitler’s 
Germany. He was a researcher in the Sir William Dunn School of 
Pathology headed by pathologist Howard Florey. Chain came across 
Fleming’s 1929 report and convinced Florey that research on penicillin 
would be of interest and scientific value. Chain collected about 200 
references on growth inhibitions caused by the action of bacteria, 
streptomycetes, fungi and yeasts on one another. It was evident that 
in many cases the growth inhibition was caused by specific 
metabolites produced by the various microorganisms. In Chain’s own 
words: “However, next to nothing was known about the chemical or 
biological nature of the inhibitory substances, and it seemed an 
interesting and rewarding field of exploration.” 
penicillin. 
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 Chain was determined to isolate and characterize the chemistry 
of penicillin and this led to an extraordinary effort under difficult 
conditions in wartime England. The first problem of Chain’s small 
team was to grow Penicillium in substantial quantity on agar surfaces. 
Because limited supplies were available, they had to use an 
astonishing assortment of sterilized trays, pie dishes, gasoline cans, 
flat bottles, biscuit tins, and porcelain bedpans. Chain was successful 
in determining the thiazolidine-beta-lactam structure of penicillin, 
and was the lead author on the first paper showing the therapeutic 
effects of purified penicillin on infected rats and mice [E. Chain, H.W. 
Florey, A.D. Gardner, N.G. Heatley, M.A. Jennings, J. Orr-Ewing and 
A.G. Sanders: Penicillin as a Chemotherapeutic Agent, Lancet, Aug. 
24: 226 (1940)]. 
 Fleming, Florey and Chain shared the 1945 Nobel Prize in 
Physiology and Medicine. Perutz’s account of the penicillin story[Is 
Science Necessary?  E. Dutton, New York, 1980] notes that “only 
Fleming made the headlines, and mentions of Florey and Chain 
appeared in small print. Fleming became a world hero, while the 
names of Florey and Chain and their colleagues have remained  
unknown outside the world of science. . . . Fleming spent the 
remaining ten years of his life collecting twenty-five honorary degrees, 
twenty-six medals, eighteen prizes, thirteen decorations, the freedom 
of fifteen cities, and honorary membership in eighty-nine scientific 
academies and societies. . . . Effusive admirers soon hailed him as the 
greatest scientific genius of all time, and he became the subject of 
several “hero-worshiping biographies.”  
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 The original strain of Pencillium notatum studied by Fleming 
produced relatively small amounts of penicillin. A related organism, P. 
chrysogenum, isolated in 1951, was more useful; it produced about 60 
mg of the antibiotic per liter of growth medium. However, this was 
still too small a yield to form the basis of an industrial isolation 
process. Over a number of years, several groups of scientists 
systematically investigated P. chrysogenum with the aim of isolating 
mutant strains that secreted more of the antibiotic. Strain E-15.1, the 
“final strain,” produced 7000 mg of penicillin per liter, and after other 
improvements, the yield reached 20,000 mg per liter. 
 In 1948, Chain left Oxford to organize the International Centre 
for Chemical Microbiology at the Istituto Superiore di Sanita in Rome. 
There, he and his colleagues pursued research in a number of fields. A 
new strong interest was development of industrial-scale fermentation 
pilot plants as research tools. This continued when Chain moved back 
to England in 1964 to become head of the Department of Biochemistry 
at the Imperial College of Science and Technology (London); Chain’s 
activities in Rome and at Imperial College were reviewed in a 1991 
article in Nature [by his son, B. Chain; vol. 353; pp. 492-494]. The 
keynote caption of the article is “The discovery of penicillin remains 
one of the greatest advances in medical science.  From the success of 
the discovery the biotechnology industry became established.” 
 “Influenced by his experiences during the first frustrating 
attempts at scaling-up penicillin production in the Oxford laboratories 
using antiquated and inappropriate technologies, Chain was convinced 
that progress in isolation and characterization of biologically active 
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substances (not only antibiotics, but vitamins, hormones, growth 
factors and other biological molecules active at very low 
concentrations) absolutely required large scale production of biological 
material. . . .Chain’s own career also predisposed him to an 
interdisciplinary approach to scientific problems. He trained as an 
organic chemist, turned later to biochemistry, and ultimately became 
interested in bioengineering. . . .Both in Rome and later in London, 
Chain’s ambitions to work on a scale unprecedented within an 
academic biochemistry department were fulfilled.” 
 (Sir Ernst) Chain published a detailed history of the penicillin 
story, from Fleming’s observations of penicillin action on the famous 
Petri dish, to the status of penicillin therapy in 1971 [Thirty years of 
penicillin therapy; Proc. Roy. Soc. London B 179: 293-319]. It is an 
outstanding paper in the annals of scientific discovery.  He notes: 
 “I started to work on penicillin in 1938, long before the outbreak 
  of the war.  The frequently repeated statement that the work 
          was started as a contribution to the war effort, to find a chemo- 
          therapeutic agent suitable for the treatment of infected war  
          wounds, has no basis. The only reason which motivated me to  
          start the work on penicillin was scientific interest.  I very much  
          doubt, in fact, whether I would have been allowed to study 
 this  problem at that time in one of the so-called ‘mission  
 oriented’ practically minded industrial laboratories. The  
 research on penicillin which was started as a problem of purely  
 scientific interest, but had consequences of very great practical  
 importance is a good example of how difficult it is to  
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 demonstrate sharp limits between pure and applied research.” 
 
 Chain discusses the problems of antibiotic-resistant pathogenic 
bacteria and reviews the immense efforts expended in searching for 
new antibiotics of clinical usefulness. There are probably lessons to be 
learned even today from Chain’s comments on the complex relations 
between academia and industry. 
 
 During the mid-1940s, Lederberg and I were in graduate school 
(at different universities) and we met at annual meetings of the 
American Society for Microbiology. He was already giving spectacular 
talks and clearly was destined to become an outstanding luminary. A 
retrospective in ASBMB  Today  (American Society of Biochemistry 
and Molecular Biology) gives an excellent succinct survey of his 
academic career (April 2008, p. 15). Part of the retrospective 
summarizes his famous experiments demonstrating basic features of 
bacterial genetics, which paved the way for making bacteria and 
bacteriophages model systems in the development of molecular biology 
and later, of applications in biotech. 
Joshua Lederberg (1925-2008) 
 “Lederberg was born in Montclair, New Jersey, in 1925 and was 
raised in New York City. He enrolled at Columbia University where he 
met Francis J. Ryan, who introduced him to the red bread mold, 
Neurospora. Lederberg received his bachelor’s degree in 1944 and 
began working toward an M.D. at Columbia University’s College of 
Physicians and Surgeons. Although medical students were not 
 18 
encouraged to do research, Lederberg continued to do experiments 
under Ryan’s supervision, investigating the genetics of bacteria. 
 “In 1946, Lederberg took a leave of absence from medical school 
to carry out experiments on Escherichia coli in collaboration with 
Edward L. Tatum at Yale University. He demonstrated that certain 
strains of bacteria undergo a sexual stage during which they mate and 
exchange genes. At the time, scientists believed that bacteria 
reproduced asexually, so Lederberg’s discovery of bacterial 
recombination was a radical one. He and Tatum were also able to map 
the E. coli chromosome, showing the locations of several of its genes. 
With Tatum’s support Lederberg submitted this research as his 
doctoral thesis and received his Ph.D. from Yale in 1947. 
 “Rather than go back to medical school, Lederberg decided to 
accept the offer of an assistant professorship in genetics at the 
University of Wisconsin at Madison. There, he continued to study 
bacterial genetics and produced a steady stream of techniques and 
results that became the basis of genetic engineering in the 1970s. His 
most important discoveries at the time were that of transduction, the 
transfer of genetic fragments from one cell to another by a virus, and 
of the extra-chromosomal genetic particles called plasmids. . . . 
 “In 1957, Lederberg helped found and became chairman of a new 
Department of Medical Genetics at the University of Wisconsin. One 
year later, he accepted an offer to become the first chairman of the 
newly established Department of Genetics at Stanford University’s 
School of Medicine. Later that year, he was awarded the 1958 Nobel 
 19 
Prize in Physiology or Medicine, along with Tatum and George W. 
Beadle.” 
 A more detailed description of Lederberg’s accomplishments by 
Gerald Weissmann can be found in The FASEB Journal 22:3411-3414, 
2008 [Science as Oath and Testimony: Joshua Lederberg (1925-2008)]. 
 Lederberg’s experimental work was only one aspect of his 
erudition and wide knowledge of the sciences, medicine, and human 
affairs. I valued his judgment on controversial questions in 
microbiology and we maintained a relevant correspondence over many 
years. We exchanged reprints, and even a partial list of the papers he 
sent me shows his extraordinary intelligence and knowledge.  He was 
really in a class all by himself. 
 
 Forty years of genetic recombination in bacteria. 
Titles of some of Lederberg’s papers in my file: 
    Nature 324: 627-628, 1986 
 Genetic recombination in bacteria: A discovery account. 
    Ann. Rev. Genet. 21: 23-46, 1987 
 How DENDRAL was conceived and born.  In: ACM Conference 
    on the History of Medical Informatics, pp. 5-24.  Association 
    for Computing Machinery, N.Y., 1987. 
 The second century of Louis Pasteur: A global agenda for 
    biomedical research.  Molecular Biology and Infectious 
              Diseases, Elsevier, Paris, pp. 19-30, 1988. 
 Pandemic as a natural evolutionary phenomenon. 
     Social Research 55: 343-359, 1988. 
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 Ontogeny of the clonal selection theory of antibody formation. 
     Reflections on Darwin and Ehrlich.  Molecular Basis of the 
             Immune Response, vol 546 of the Annals of the New York  
             Academy of Sciences, pp. 175-187, 1988. 
 The Gene (H.J. Muller 1947).  In: Anecdotal, Historical and 
              Critical Commentaries on Genetics. Genetics 129: 313-316,  
              1991. 
 The interface of science and medicine.  Mount Sinai J. of Med. 
              59: 380-383, 1992. 
         Bacterial variation since Pasteur / Rummaging in the attic: 
       Antiquarian ideas of transmissible heredity, 1880-1940. 
       Amer. Soc. Microbiol. News 58: 261-265, 1992. 
 What the double helix (1953) has meant for basic biomedical  
      science /A personal commentary.  J. Am. Med. Assoc. 269: 
              1981-1985, 1993. 
 Smaller fleas. . . ad infinitum:  Therapeutic bacteriophage redux. 
      Proc. Natl. Acad. Sci. 93: 3167-3168, 1996.   Inscribed: “I 
       should have recalled your discussion on this in Perspectives 
              1993.”  JL. 
 Some early stirrings (1950 ff.) of concern about environmental 
      mutagens.  Environ. & Molec. Mutagenesis 30: 3-10, 1997. 
 
 In the 1992 paper in American Society for Microbiology News, 
there is a box, based on an interview with Lederberg. It notes that 
from 1978 to 1990, he served as President of Rockefeller University. 
Then, as a University Professor, he continued research in the field of 
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transcriptional specificities in mutagenesis in bacteria. Some of his 
remarks are still cogent: 
 “Even though we’ve seen some dimming of unblinking support 
for scientific research, and molecular biology is of course much more 
crowded, any of my students still has a crack at revolutionary 
discovery if they will but seize the day,” he said. 
   “Although public scrutiny of scientific research and standards 
of accountability are more stringent, perhaps more hostile than in the 
recent past, Lederberg doesn’t see a recrudescence of scientific 
McCarthyism.  “Yes, the screws are a little bit tighter, and people are 
going to look more closely at marginal research, including plagiarism 
as well as imputed fraud. However, anyone who exercises a modicum 
of common sense and integrity has no rational basis for being 
deterred. 
    “Unfortunately, social vigilance about the integrity of scientific 
research may create the impression that the discipline is loaded with 
crooks and predators,” Lederberg said. “We urgently need to dispel the 
idea that the that the primary motivation of researchers is to beat 
their competitors. I firmly believe that idealism and the excitement of 
discovery are necessary parts of science.”  (Italics added) 
 
 Lederberg, like Perutz, had a strong interest in the history and 
sociology of scientific research. He noted that “Missing from most primary 
literature in science are all but the faintest clues about the social context of 
discovery—how the scientific community is shaped by its operating norms 
More on history 
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and institutions, as well as by its fraternal and intergenerational 
networks….Biography depicts directly the personal relationships among 
scientists, their mutual debts, their etiquettes, sometimes their jealousies and 
transgressions.” [see his introduction to The Excitement and Fascination of 
Science: Reflections by Eminent Scientists, Vol.3, Part 1 (Ann. Reviews, 
Palo Alto, CA (1990). Unusual insights into this aspect of scientific life were 
provided by bacteriologist Dr. Claude Dolman, who was a professor at the 
University of British Columbia for many years.  
Dolman received his medical education at St. Mary’s Hospital 
Medical School (London), where Alexander Fleming was one of his 
teachers. During the early 1960s he renounced “the lure of the laboratory 
and the comforts of home” for 8 months “in order to go around the world  
gleaning a few bundles of historical straws.” He traveled to 4 continents and 
15 countries where he interviewed “many scores of distinguished persons.” 
The journey was summarized in his interesting and informative paper 
“Tidbits of Bacteriological History” [Canad. J. Public Health 53: 269-278, 
1962]. Dolman describes an episode of unexpected value when he paid a 
courtesy call to the widow of William Bulloch, who wrote the most 
authoritative  history of bacteriology up to the 20th century (see Further 
Reading). She offered him a trunkful of Bulloch’s papers, which contained 
working notes, illustrations and other material relating to his classic book. 
A few of Dolman’s remarks: “Too many younger scientists nowadays 
find it tempting to clarify an issue by doing an experiment rather than by 
first seeking the answer in the literature. Though I found no evidence that 
our predecessors were on the whole significantly more ascetic, less clay-
footed, pleasanter personalities or better world-citizens than their 
counterparts today, yet still their achievements merit our homage. For they 
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were heirs to centuries of wishful thinking, of groping speculation, of 
controversial dogmas, of voices crying in the wilderness; and they dedicated 
diversities of gifts and dauntless courage to prophesying, unraveling, 
demonstrating and harnessing for the good of mankind those invisible agents 
of previously unimagined complexity, to whose mastery most of us owe our 
survival, and by manipulating which we as a group earn our livelihood . To 
deny them honour by arguing that if they had not done their work so well 
others soon enough would have found the way, is to make a mockery of 
history and a plaything of science.” 
Dr. Dolman (1906-1994) assembled a large and priceless collection of 
rare books on many aspects of microbiology and immunology, some dating 
back to the 16th century. The Dolman Collection is in the I.K. Barber 
Learning Centre of the Point Grey Campus of the University of British 
Columbia, Vancouver. 
 
 Obviously, there is no such thing as THE  Scientific Life.  We can 
certainly expect that an increasing variety of “9-to-5” technoscience 
jobs will develop in the future.  Many, perhaps most, of them will not 
include basic research as it is usually understood.  Academic science 
careers will continue in the usual pattern despite the chronic problems 
of obtaining financial support for research at the frontiers. I expect 
that the top universities will manage to preserve older academic 
traditions, while many others will gradually tailor graduate studies to 
train technoscientists. 
Summing Up 
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 Despite all its problems, academic basic research is still a long 
way ahead of Shapin’s brave new world of technoscience/finance 
development.  Research at the frontiers of basic knowledge is not the 
real subject of his book, whose title is misleading. The 
Technoscience/Financial Vocation would have been more descriptive.  
Essentially, it is all about making money from the scientific fruits 
grown mainly in academia and non-profit institutes.  Nowadays, 
leading science magazines (Nature, Science) frequently include special 
sections about careers in biotech, biopharmaceutical corporations, etc.  
They discuss the ups and downs of “corporate culture.” The business 
sections of major newspapers routinely publish relevant articles.  A 
long report in the New York Times of March 10, 2009 is illustrative—
key words and phrases: 
 Drug investors, losing patience, demand cash from companies; 
unsuccessful biotech company’s quest for the next blockbuster; mega-
mergers; second quarter dividends; controversial reverse mergers; 
“zombies” – companies that lurch from product to product, surviving 
years or even decades without ever achieving success; tender offers. 
One searches such reports in vain for news on fundamental research 
advances. 
 There are some attempts to modify the typical so-called 
“entrepreneurial model” in biotech. Genentech has 11,000 employees 
and about 100 billion dollars in market capitalization and boasts 
having 120 postdocs (trained in academia) in a “relaxed culture.” 
According to their new executive vice president for “research and early 
development,” Genentech plans to make sure that their scientists 
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“continue to have time to work on their own projects that aren’t 
translational [i.e., to products], that aren’t governed in any specific 
way, and that scientists have time to think and imagine and invent, 
not just do routine things.”  Incidentally, the laid back work 
environment features Friday night keg parties.  [See Science 324: p. 
583 (1 May 2009).   
 The oasis of academia at Genentech apparently does not include 
the time-consuming burden of teaching basic subjects to the next 
generation of scientists.  We can expect that sooner or later, 
Genentech will have to develop a new generation of blockbuster drugs 
to keep up with the competition (such as from Roche, which has  
80,000 employees). At the other end of the spectrum, multitudes of 
small start-up biotechs are teetering on the brink, praying that 
someone will buy them out. 
 Yes, many aspects of “scientific lives” involve gambles and, 
sometime, sacrifices. You have to decide what drives you and provides 
the most satisfactions; which, of course, is really not news. 
 
 More about the lives and research of eminent scientists can be 
found in the following: 
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